Clinical Trials | June 18, 2026
Suven reports positive Phase 2b results for Ropanicant in major depressive disorder
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
Samelisant will be the centerpiece of Suven’s scientific presence
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
The change of name has been carried on pursuant to the Scheme of Amalgamation
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
